Dermatology Times is looking back on the top stories in dermatology from the month of October.
|Articles|January 1, 2004
Understanding chemoprevention
Author(s)Michelle Stephenson
Tucker, Ga. - Three mechanisms are purported to induce cutaneous malignancies: initiating events, promotional effects, and effects on the immune system, according to Kathleen J. Smith, M.D., from Quest Diagnostics.
Advertisement
Advertisement
Related to this article
From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
October Social Media Mythbusters: 3 Viral Beauty Claims, Debunked
3
Interpreting Scalp and Nail Efficacy Data for Psoriasis Biologics
4
A Patient's Psoriasis Journey: From Topicals to Biologic Therapy
5